Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

EOMES interacts with RUNX3 and BRG1 to promote innate memory cell formation through epigenetic reprogramming.

Istaces N, Splittgerber M, Lima Silva V, Nguyen M, Thomas S, Le A, Achouri Y, Calonne E, Defrance M, Fuks F, Goriely S, Azouz A.

Nat Commun. 2019 Jul 24;10(1):3306. doi: 10.1038/s41467-019-11233-6.

2.

TET2-Dependent Hydroxymethylome Plasticity Reduces Melanoma Initiation and Progression.

Bonvin E, Radaelli E, Bizet M, Luciani F, Calonne E, Putmans P, Nittner D, Singh NK, Santagostino SF, Petit V, Larue L, Marine JC, Fuks F.

Cancer Res. 2019 Feb 1;79(3):482-494. doi: 10.1158/0008-5472.CAN-18-1214. Epub 2018 Dec 11.

PMID:
30538121
3.

Comprehensive identification of long noncoding RNAs in colorectal cancer.

James de Bony E, Bizet M, Van Grembergen O, Hassabi B, Calonne E, Putmans P, Bontempi G, Fuks F.

Oncotarget. 2018 Jun 12;9(45):27605-27629. doi: 10.18632/oncotarget.25218. eCollection 2018 Jun 12.

4.

Immunity drives TET1 regulation in cancer through NF-κB.

Collignon E, Canale A, Al Wardi C, Bizet M, Calonne E, Dedeurwaerder S, Garaud S, Naveaux C, Barham W, Wilson A, Bouchat S, Hubert P, Van Lint C, Yull F, Sotiriou C, Willard-Gallo K, Noel A, Fuks F.

Sci Adv. 2018 Jun 20;4(6):eaap7309. doi: 10.1126/sciadv.aap7309. eCollection 2018 Jun.

5.

Positioning Europe for the EPITRANSCRIPTOMICS challenge.

Jantsch MF, Quattrone A, O'Connell M, Helm M, Frye M, Macias-Gonzales M, Ohman M, Ameres S, Willems L, Fuks F, Oulas A, Vanacova S, Nielsen H, Bousquet-Antonelli C, Motorin Y, Roignant JY, Balatsos N, Dinnyes A, Baranov P, Kelly V, Lamm A, Rechavi G, Pelizzola M, Liepins J, Holodnuka Kholodnyuk I, Zammit V, Ayers D, Drablos F, Dahl JA, Bujnicki J, Jeronimo C, Almeida R, Neagu M, Costache M, Bankovic J, Banovic B, Kyselovic J, Valor LM, Selbert S, Pir P, Demircan T, Cowling V, Schäfer M, Rossmanith W, Lafontaine D, David A, Carre C, Lyko F, Schaffrath R, Schwartz S, Verdel A, Klungland A, Purta E, Timotijevic G, Cardona F, Davalos A, Ballana E, O Carroll D, Ule J, Fray R.

RNA Biol. 2018;15(6):829-831. doi: 10.1080/15476286.2018.1460996. Epub 2018 May 9.

6.

Correction to: Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.

Wang Y, He T, Herman JG, Linghu E, Yang Y, Fuks F, Zhou F, Song L, Guo M.

Clin Epigenetics. 2018 Mar 14;10:36. doi: 10.1186/s13148-018-0467-2. eCollection 2018.

7.

The transcription factors Runx3 and ThPOK cross-regulate acquisition of cytotoxic function by human Th1 lymphocytes.

Serroukh Y, Gu-Trantien C, Hooshiar Kashani B, Defrance M, Vu Manh TP, Azouz A, Detavernier A, Hoyois A, Das J, Bizet M, Pollet E, Tabbuso T, Calonne E, van Gisbergen K, Dalod M, Fuks F, Goriely S, Marchant A.

Elife. 2018 Feb 28;7. pii: e30496. doi: 10.7554/eLife.30496.

8.

Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma.

Guo Y, Peng Y, Gao D, Zhang M, Yang W, Linghu E, Herman JG, Fuks F, Dong G, Guo M.

Clin Epigenetics. 2017 Oct 23;9:116. doi: 10.1186/s13148-017-0412-9. eCollection 2017.

9.

Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth.

Wang Y, He T, Herman JG, Linghu E, Yang Y, Fuks F, Zhou F, Song L, Guo M.

Clin Epigenetics. 2017 Oct 18;9:115. doi: 10.1186/s13148-017-0417-4. eCollection 2017. Erratum in: Clin Epigenetics. 2018 Mar 14;10 :36.

10.

DNA methylation-based immune response signature improves patient diagnosis in multiple cancers.

Jeschke J, Bizet M, Desmedt C, Calonne E, Dedeurwaerder S, Garaud S, Koch A, Larsimont D, Salgado R, Van den Eynden G, Willard Gallo K, Bontempi G, Defrance M, Sotiriou C, Fuks F.

J Clin Invest. 2017 Aug 1;127(8):3090-3102. doi: 10.1172/JCI91095. Epub 2017 Jul 17.

11.

Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development.

Gao D, Han Y, Yang Y, Herman JG, Linghu E, Zhan Q, Fuks F, Lu ZJ, Guo M.

Epigenetics. 2017 Jul 3;12(7):575-583. doi: 10.1080/15592294.2017.1341027. Epub 2017 Jul 5.

12.

Meeting Report of the Fifth International Cancer Epigenetics Conference in Beijing, China, October 2016.

Gao D, Herman JG, Cui H, Jen J, Fuks F, Brock MV, Ushijima T, Croce C, Akiyama Y, Guo M.

Epigenomics. 2017 Jul;9(7):937-941. doi: 10.2217/epi-2017-0030. Epub 2017 May 22.

13.

FOXP1 is a regulator of quiescence in healthy human CD4+ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders.

Garaud S, Roufosse F, De Silva P, Gu-Trantien C, Lodewyckx JN, Duvillier H, Dedeurwaerder S, Bizet M, Defrance M, Fuks F, Bex F, Willard-Gallo K.

Eur J Immunol. 2017 Jan;47(1):168-179. doi: 10.1002/eji.201646373. Epub 2016 Nov 30.

14.

Portraying breast cancers with long noncoding RNAs.

Van Grembergen O, Bizet M, de Bony EJ, Calonne E, Putmans P, Brohée S, Olsen C, Guo M, Bontempi G, Sotiriou C, Defrance M, Fuks F.

Sci Adv. 2016 Sep 2;2(9):e1600220. doi: 10.1126/sciadv.1600220. eCollection 2016 Sep.

15.

The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent.

Brenner C, Luciani J, Bizet M, Ndlovu M, Josseaux E, Dedeurwaerder S, Calonne E, Putmans P, Cartron PF, Defrance M, Fuks F, Deplus R.

Oncotarget. 2016 Sep 13;7(37):58939-58952. doi: 10.18632/oncotarget.10624.

16.

Portraits of TET-mediated DNA hydroxymethylation in cancer.

Jeschke J, Collignon E, Fuks F.

Curr Opin Genet Dev. 2016 Feb;36:16-26. doi: 10.1016/j.gde.2016.01.004. Epub 2016 Feb 12. Review.

PMID:
26875115
17.

RNA biochemistry. Transcriptome-wide distribution and function of RNA hydroxymethylcytosine.

Delatte B, Wang F, Ngoc LV, Collignon E, Bonvin E, Deplus R, Calonne E, Hassabi B, Putmans P, Awe S, Wetzel C, Kreher J, Soin R, Creppe C, Limbach PA, Gueydan C, Kruys V, Brehm A, Minakhina S, Defrance M, Steward R, Fuks F.

Science. 2016 Jan 15;351(6270):282-5. doi: 10.1126/science.aac5253.

18.

MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.

Denis H, Van Grembergen O, Delatte B, Dedeurwaerder S, Putmans P, Calonne E, Rothé F, Sotiriou C, Fuks F, Deplus R.

Mol Biosyst. 2016 Feb;12(2):404-13. doi: 10.1039/c5mb00513b.

PMID:
26621457
19.

Genome-wide hydroxymethylcytosine pattern changes in response to oxidative stress.

Delatte B, Jeschke J, Defrance M, Bachman M, Creppe C, Calonne E, Bizet M, Deplus R, Marroquí L, Libin M, Ravichandran M, Mascart F, Eizirik DL, Murrell A, Jurkowski TP, Fuks F.

Sci Rep. 2015 Aug 4;5:12714. doi: 10.1038/srep12714.

20.

Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth.

Dong Y, Cao B, Zhang M, Han W, Herman JG, Fuks F, Zhao Y, Guo M.

Oncotarget. 2015 Sep 8;6(26):22126-38.

21.

Sox9 Controls Self-Renewal of Oncogene Targeted Cells and Links Tumor Initiation and Invasion.

Larsimont JC, Youssef KK, Sánchez-Danés A, Sukumaran V, Defrance M, Delatte B, Liagre M, Baatsen P, Marine JC, Lippens S, Guerin C, Del Marmol V, Vanderwinden JM, Fuks F, Blanpain C.

Cell Stem Cell. 2015 Jul 2;17(1):60-73. doi: 10.1016/j.stem.2015.05.008. Epub 2015 Jun 18.

22.

5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer.

Uribe-Lewis S, Stark R, Carroll T, Dunning MJ, Bachman M, Ito Y, Stojic L, Halim S, Vowler SL, Lynch AG, Delatte B, de Bony EJ, Colin L, Defrance M, Krueger F, Silva AL, Ten Hoopen R, Ibrahim AE, Fuks F, Murrell A.

Genome Biol. 2015 Apr 1;16:69. doi: 10.1186/s13059-015-0605-5.

23.

DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.

Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, Li Y, Ahn J, Abdel-Wahab O, Shih A, Lu C, Ward PS, Tsai JJ, Hricik T, Tosello V, Tallman JE, Zhao X, Daniels D, Dai Q, Ciminio L, Aifantis I, He C, Fuks F, Tallman MS, Ferrando A, Nimer S, Paietta E, Thompson CB, Licht JD, Mason CE, Godley LA, Melnick A, Figueroa ME, Levine RL.

Cell Rep. 2014 Dec 11;9(5):1841-1855. doi: 10.1016/j.celrep.2014.11.004. Epub 2014 Dec 4.

24.

DNA methylome profiling beyond promoters - taking an epigenetic snapshot of the breast tumor microenvironment.

Jeschke J, Collignon E, Fuks F.

FEBS J. 2015 May;282(9):1801-14. doi: 10.1111/febs.13125. Epub 2014 Nov 24.

25.

Rhino facial zygomycosis: case report.

Miguita e Souza J, Sproesser Junior AJ, Felippu Neto A, Fuks FB, Oliveira CA.

Einstein (Sao Paulo). 2014 Sep;12(3):347-50. Epub 2014 Aug 21. English, Portuguese.

26.

Regulation of DNA methylation patterns by CK2-mediated phosphorylation of Dnmt3a.

Deplus R, Blanchon L, Rajavelu A, Boukaba A, Defrance M, Luciani J, Rothé F, Dedeurwaerder S, Denis H, Brinkman AB, Simmer F, Müller F, Bertin B, Berdasco M, Putmans P, Calonne E, Litchfield DW, de Launoit Y, Jurkowski TP, Stunnenberg HG, Bock C, Sotiriou C, Fraga MF, Esteller M, Jeltsch A, Fuks F.

Cell Rep. 2014 Aug 7;8(3):743-53. doi: 10.1016/j.celrep.2014.06.048. Epub 2014 Jul 24.

27.

Citrullination of DNMT3A by PADI4 regulates its stability and controls DNA methylation.

Deplus R, Denis H, Putmans P, Calonne E, Fourrez M, Yamamoto K, Suzuki A, Fuks F.

Nucleic Acids Res. 2014 Jul;42(13):8285-96. doi: 10.1093/nar/gku522. Epub 2014 Jun 23.

28.

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma.

Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, Brohée S, Salmon I, Dubois C, del Marmol V, Fuks F, Beck B, Blanpain C.

Nature. 2014 Jul 10;511(7508):246-50. doi: 10.1038/nature13305. Epub 2014 Jun 8.

PMID:
24909994
29.

Playing TETris with DNA modifications.

Delatte B, Deplus R, Fuks F.

EMBO J. 2014 Jun 2;33(11):1198-211. doi: 10.15252/embj.201488290. Epub 2014 May 13. Review.

30.

Dietary flavanols modulate the transcription of genes associated with cardiovascular pathology without changes in their DNA methylation state.

Milenkovic D, Vanden Berghe W, Boby C, Leroux C, Declerck K, Szarc vel Szic K, Heyninck K, Laukens K, Bizet M, Defrance M, Dedeurwaerder S, Calonne E, Fuks F, Haegeman G, Haenen GR, Bast A, Weseler AR.

PLoS One. 2014 Apr 24;9(4):e95527. doi: 10.1371/journal.pone.0095527. eCollection 2014.

31.

TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells.

Langlois T, da Costa Reis Monte-Mor B, Lenglet G, Droin N, Marty C, Le Couédic JP, Almire C, Auger N, Mercher T, Delhommeau F, Christensen J, Helin K, Debili N, Fuks F, Bernard OA, Solary E, Vainchenker W, Plo I.

Stem Cells. 2014 Aug;32(8):2084-97. doi: 10.1002/stem.1718.

32.

The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.

Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W.

Leukemia. 2014 Mar;28(3):485-96. doi: 10.1038/leu.2013.337. Epub 2013 Nov 13. Review.

PMID:
24220273
33.

Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer.

Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, Zhu H, Li Y, Yang Y, Guo M.

Epigenetics. 2013 Dec;8(12):1373-83. doi: 10.4161/epi.26781. Epub 2013 Oct 22.

34.

A comprehensive overview of Infinium HumanMethylation450 data processing.

Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F.

Brief Bioinform. 2014 Nov;15(6):929-41. doi: 10.1093/bib/bbt054. Epub 2013 Aug 29. Review.

35.

TET proteins: on the frenetic hunt for new cytosine modifications.

Delatte B, Fuks F.

Brief Funct Genomics. 2013 May;12(3):191-204. doi: 10.1093/bfgp/elt010. Epub 2013 Apr 26. Review.

36.

TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS.

Deplus R, Delatte B, Schwinn MK, Defrance M, Méndez J, Murphy N, Dawson MA, Volkmar M, Putmans P, Calonne E, Shih AH, Levine RL, Bernard O, Mercher T, Solary E, Urh M, Daniels DL, Fuks F.

EMBO J. 2013 Mar 6;32(5):645-55. doi: 10.1038/emboj.2012.357. Epub 2013 Jan 25.

37.

DNA methylation markers for breast cancer prognosis: Unmasking the immune component.

Dedeurwaerder S, Fuks F.

Oncoimmunology. 2012 Sep 1;1(6):962-964.

38.

Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesis.

Guenin S, Mouallif M, Deplus R, Lampe X, Krusy N, Calonne E, Delbecque K, Kridelka F, Fuks F, Ennaji MM, Delvenne P.

PLoS One. 2012;7(8):e42704. doi: 10.1371/journal.pone.0042704. Epub 2012 Aug 3.

39.

The histone demethylase Kdm3a is essential to progression through differentiation.

Herzog M, Josseaux E, Dedeurwaerder S, Calonne E, Volkmar M, Fuks F.

Nucleic Acids Res. 2012 Aug;40(15):7219-32. doi: 10.1093/nar/gks399. Epub 2012 May 11.

40.

DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients.

Volkmar M, Dedeurwaerder S, Cunha DA, Ndlovu MN, Defrance M, Deplus R, Calonne E, Volkmar U, Igoillo-Esteve M, Naamane N, Del Guerra S, Masini M, Bugliani M, Marchetti P, Cnop M, Eizirik DL, Fuks F.

EMBO J. 2012 Mar 21;31(6):1405-26. doi: 10.1038/emboj.2011.503. Epub 2012 Jan 31.

41.

Evaluation of the Infinium Methylation 450K technology.

Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F.

Epigenomics. 2011 Dec;3(6):771-84. doi: 10.2217/epi.11.105.

42.

Unravelling the epigenomic dimension of breast cancers.

Dedeurwaerder S, Fumagalli D, Fuks F.

Curr Opin Oncol. 2011 Nov;23(6):559-65. doi: 10.1097/CCO.0b013e32834bd481. Review.

PMID:
21946247
43.

DNA methylation profiling reveals a predominant immune component in breast cancers.

Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, van Baren N, Coulie PG, Piccart M, Sotiriou C, Fuks F.

EMBO Mol Med. 2011 Dec;3(12):726-41. doi: 10.1002/emmm.201100801. Epub 2011 Nov 16.

44.

Regulation of mammalian DNA methyltransferases: a route to new mechanisms.

Denis H, Ndlovu MN, Fuks F.

EMBO Rep. 2011 Jul 1;12(7):647-56. doi: 10.1038/embor.2011.110. Review.

45.

Exposing the DNA methylome iceberg.

Ndlovu MN, Denis H, Fuks F.

Trends Biochem Sci. 2011 Jul;36(7):381-7. doi: 10.1016/j.tibs.2011.03.002. Epub 2011 Apr 14. Review.

PMID:
21497094
46.

Journal club. A cancer biologist marvels at how key gene regulators are still revealing hidden talents.

Fuks F.

Nature. 2010 Jul 22;466(7305):417. doi: 10.1038/466417f. No abstract available.

PMID:
20651654
47.

Functional connection between deimination and deacetylation of histones.

Denis H, Deplus R, Putmans P, Yamada M, Métivier R, Fuks F.

Mol Cell Biol. 2009 Sep;29(18):4982-93. doi: 10.1128/MCB.00285-09. Epub 2009 Jul 6.

48.

Atonal homolog 1 is a tumor suppressor gene.

Bossuyt W, Kazanjian A, De Geest N, Van Kelst S, De Hertogh G, Geboes K, Boivin GP, Luciani J, Fuks F, Chuah M, VandenDriessche T, Marynen P, Cools J, Shroyer NF, Hassan BA.

PLoS Biol. 2009 Feb 24;7(2):e39. doi: 10.1371/journal.pbio.1000039.

49.

De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes.

Epsztejn-Litman S, Feldman N, Abu-Remaileh M, Shufaro Y, Gerson A, Ueda J, Deplus R, Fuks F, Shinkai Y, Cedar H, Bergman Y.

Nat Struct Mol Biol. 2008 Nov;15(11):1176-1183. doi: 10.1038/nsmb.1476. Epub 2008 Oct 26.

50.

Reduced tumorigenesis in mouse mammary cancer cells following inhibition of Pea3- or Erm-dependent transcription.

Firlej V, Ladam F, Brysbaert G, Dumont P, Fuks F, de Launoit Y, Benecke A, Chotteau-Lelievre A.

J Cell Sci. 2008 Oct 15;121(Pt 20):3393-402. doi: 10.1242/jcs.027201. Epub 2008 Sep 30.

Supplemental Content

Support Center